Skip to main content

Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.

Publication ,  Journal Article
Marquis-Gravel, G; Roe, MT; Harrington, RA; Muñoz, D; Hernandez, AF; Jones, WS
Published in: Circulation
September 24, 2019

Aspirin is the cornerstone of the antithrombotic management of patients with established atherosclerotic cardiovascular disease, but major guidelines provide conflicting recommendations for its use in primary prevention. Findings from recent randomized trials totaling >47 000 patients called into question the net clinical benefits of aspirin in primary prevention for 3 key populations: patients with diabetes mellitus, community-dwelling elderly individuals, and patients without diabetes mellitus who are at intermediate risk for atherosclerotic events. In the context of increasing emphasis on the use of other treatments for primary prevention in patients with moderate-high future risk of developing atherosclerotic cardiovascular disease, the efficacy and safety of aspirin for primary prevention has become uncertain. Key unresolved questions regarding the role of aspirin in primary prevention include the optimal drug formulation, dosing schedule, weight-based dose selection, and interplay between sex and treatment response. In the current era, most patients without established atherosclerotic cardiovascular disease should not be prescribed aspirin. Rather, aggressive management of comorbidities tailored to the expected cardiovascular risk needs to be emphasized. In this context, informed shared decision making between clinicians and patients regarding the use of aspirin for primary prevention of cardiovascular events is a suitable and laudable approach. In this article, we revisit the role of aspirin for the primary prevention of cardiovascular diseases by critically reviewing the key scientific literature, highlight key areas of uncertainties for future research, and propose a decisional framework for clinicians to support prescription of aspirin in primary prevention.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

September 24, 2019

Volume

140

Issue

13

Start / End Page

1115 / 1124

Location

United States

Related Subject Headings

  • Risk Factors
  • Risk
  • Primary Prevention
  • Humans
  • Fibrinolytic Agents
  • Drug Dosage Calculations
  • Clinical Trials as Topic
  • Clinical Protocols
  • Clinical Decision-Making
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Marquis-Gravel, G., Roe, M. T., Harrington, R. A., Muñoz, D., Hernandez, A. F., & Jones, W. S. (2019). Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation, 140(13), 1115–1124. https://doi.org/10.1161/CIRCULATIONAHA.119.040205
Marquis-Gravel, Guillaume, Matthew T. Roe, Robert A. Harrington, Daniel Muñoz, Adrian F. Hernandez, and W Schuyler Jones. “Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.Circulation 140, no. 13 (September 24, 2019): 1115–24. https://doi.org/10.1161/CIRCULATIONAHA.119.040205.
Marquis-Gravel G, Roe MT, Harrington RA, Muñoz D, Hernandez AF, Jones WS. Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation. 2019 Sep 24;140(13):1115–24.
Marquis-Gravel, Guillaume, et al. “Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.Circulation, vol. 140, no. 13, Sept. 2019, pp. 1115–24. Pubmed, doi:10.1161/CIRCULATIONAHA.119.040205.
Marquis-Gravel G, Roe MT, Harrington RA, Muñoz D, Hernandez AF, Jones WS. Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation. 2019 Sep 24;140(13):1115–1124.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

September 24, 2019

Volume

140

Issue

13

Start / End Page

1115 / 1124

Location

United States

Related Subject Headings

  • Risk Factors
  • Risk
  • Primary Prevention
  • Humans
  • Fibrinolytic Agents
  • Drug Dosage Calculations
  • Clinical Trials as Topic
  • Clinical Protocols
  • Clinical Decision-Making
  • Cardiovascular System & Hematology